This review provides a concise summary of significant research progress on SIRT1 deacetylase in leukemia in the past year. SIRT1 is a multifunctional protein and recent studies demonstrate that SIRT1 plays a crucial role in myeloid leukemogenesis and drug resistance.
INTRODUCTION
SIRT1 is a member of mammalian sirtuins that are homologs of yeast silent information regulator 2 (Sir2) encoding a NAD-dependent histone deacetylase [1, 2] . SIRT1 shares the highest homology with yeast Sir2 and is the most extensively studied sirtuin. SIRT1 deacetylates histones, preferentially H4K16 and H1K26 [2, 3] , and is involved in gene silencing and heterochromatin formation [4] . SIRT1 regulates a wide variety of biological processes and cellular functions through deacetylating a growing list of nonhistone proteins, including transcriptional factors p53, FOXO1, FOXO3a, NF-kB, c-MYC, N-MYC and E2F1 for regulating cell-cycle progression and survival; DNA repair factors Ku70, RAD51, NBS1, APE1, XPA/C, and WRN; and nuclear receptor, circadian clock and related factors LXR, FXR, ERa, androgen receptor, PPARg, PGC1a, CLOCK, and PER2 for regulating metabolism, as detailed in previous reviews [5, 6] . This review will present an overview of SIRT1 functions in normal hematopoiesis followed by SIRT1 roles in leukemogenesis, in particular, chronic myeloid leukemia (CML), a hematopoietic stem cell malignancy caused by oncogenic fusion gene BCR-ABL [7] .
FUNCTIONS OF SIRT1 IN NORMAL HEMATOPOIESIS
In the past year, Yuan et al. [8 && ] and Li et al. [9 && ] demonstrated that SIRT1 gene expression is low in CD34 þ normal human hematopoietic stem/ progenitor cells as compared with CML counterparts. Similarly, SIRT1 expression is generally low in mouse bone marrow hematopoietic progenitor cells, or whole mononuclear cells [8 && ]. This poor expression of SIRT1 in normal hematopoietic stem/ progenitor cells may explain why SIRT1 homozygous knockout with deletion of exons 5-7 in BALB/c mice [8 && ] or deletion of exon 4 in C57BL/6 mice [10 erythropoietin [10 & ]. These studies are in line with a previous study showing no significant in-vivo impact of SIRT1 homozygous knockout on hematopoiesis in young C57BL/6 mice [11] .
However, SIRT1 knockout notably affects hematopoiesis studied in vitro. The impact of SIRT1 loss on mouse embryonic hematopoiesis has been examined using mouse embryonic stem cells (mESCs) [12] . Mouse SIRT1 gene expression is higher in mESCs than in several somatic tissues [13] . High levels of SIRT1 help maintain self-renewal of mESCs by deacetylating p53 and preventing its translocation to the nucleus. p53 is a transcriptional repressor of Nanog, and sequestration of p53 in the cytoplasm leads to activation of Nanog expression for stem cell self-renewal [14] . mESCs are typically maintained under normoxia in a medium containing 2-mecaptoethanol, an antioxidant that prevents buildup of endogenous reactive oxygen species (ROS). The maintenance of self-renewal by SIRT1 comes at the price of increasing exposure of mESCs to ROS as cytoplasm-localized p53 fails to activate several antioxidant genes, which is manifested by the withdrawal of 2-mecaptoethanol [14] . Culturing mESCs under hypoxic conditions prevents ROS buildup even in the absence of 2-mecaptoethanol, and thus increases survival of mESCs. By in-vitro differentiation of mESCs (derived from R1 ESC line of 129 strain) to hematopoietic cells, Ou et al. [12] showed that SIRT1 homozygous knockout delays in-vitro hematopoiesis phenotypically and molecularly. Ou et al. [12] further showed that SIRT1 À/À , but not SIRT1 þ/À , yolk sac forms less primitive erythroid colonies under normoxia culture than SIRT1 þ/þ yolk sac. Recently, Matsui et al. [15] showed that when cultured in vitro, SIRT1 À/À fetal liver cells differentiate more apparently and produce less c-Kit
fetal liver cells, but there is no difference before in-vitro culture. In addition, Ou et al. [12] also showed that SIRT1 knockout mouse bone marrow cells harvested from a mixed 129/FVB/Black Swiss strain background form fewer hematopoietic progenitor colony forming unit (CFU) colonies than wild type cells, the effect being more pronounced for cells from older mice and cultured under lower oxygen as SIRT1 knockout cells do not respond to enhanced growth condition under lowered oxygen. Surprisingly, Ou et al. found that SIRT1 heterozygous knockout is nearly as effective as homozygous knockout in affecting CFU potential; however, no in-vivo mouse hematological data have been shown for comparison. The precise reason for this finding is not clear; but it is known that the SIRT1 knockout in the 129/FVB/Black strain background [16] has more severe embryonic lethality phenotype than in other strains reported so far.
ACTIVATION OF SIRT1 GENE EXPRESSION IN LEUKEMIA
SIRT1 expression is subjected to multiple layers of regulation from transcription, translation to protein functions [17] . In hematopoietic cells, SIRT1 gene expression is robustly activated by BCR-ABL and KRAS oncogenes [8 && ]. Yuan et al. [8 && ] showed that SIRT1 transcription is upregulated by BCR-ABL in CML cells in part through signal transducer and activator of transcription 5 (STAT5) that binds on two sites of the SIRT1 promoter. STAT5 is a key BCR-ABL tyrosine kinase-dependent signaling molecule in CML, and is also activated in certain forms of acute myeloid leukemia (AML) [18] . It is possible that SIRT1 can be similarly activated by other oncogenic events in certain AML through STAT5. In fact, it is reported that SIRT1 expression is increased in certain AML patients [19] . Interestingly, however, even with nearly complete inhibition of tyrosine kinase activity, Yuan et al. [8 && ] found that SIRT1 is only down by about half in CML cells, suggesting likely existence of BCR-ABL kinaseindependent activation of SIRT1. The same was seen with SIRT1 inhibition in primary CML progenitor cells [9 && ]. However, mechanisms of BCR-ABL kinase-independent activation of SIRT1 remain to be identified. As shown in Fig. 1 , SIRT1 activation by BCR-ABL affects multiple aspects of CML molecular pathobiology as detailed below.
Activation of SIRT1 by STAT5 may also bridge SIRT1 functions in non-oncogenic physiological regulation. STAT5 is a cytokine-signaling molecule for stem/progenitor cells, epithelial cells, and the immune system [20] . It is noted that incubation of mouse bone marrow cells with cytokine and growth factor cocktails elevates SIRT1 expression in culture [8 && ]. We speculate that such regulation may have
KEY POINTS
BCR-ABL activates SIRT1 through kinase-dependent STAT5 signaling and in a kinase-independent manner.
SIRT1 knockout suppresses BCR-ABL-mediated leukemogenesis.
SIRT1 promotes resistance of CML leukemic stem cells to tyrosine kinase inhibitors.
important roles in certain physiological conditions, but constitutive SIRT1 activation by oncogenic transformation disrupts signaling balance and renders substantial cell proliferation and survival advantage leading to leukemogenesis and cancer resistance, described below.
SIRT1 PROMOTES BCR-ABL MEDIATED LEUKEMOGENESIS
Roles of SIRT1 in cancer have been controversial. Previously, it was shown that SIRT1 promotes genome stability and loss of SIRT1 predisposes mice to tumorigenesis in the presence of heterozygous deletion of p53 [16] . Conditional SIRT1 overexpression reduces intestinal tumor formation in APC min/þ mice [21] , and thymic lymphoma in p53 þ/À mice [22] . Herranz et al. [23] showed that transgenic mice with SIRT1 overexpression under its own promoter have reduced spontaneous carcinomas and sarcomas, and as well as reduced incidence of carcinogeninduced liver cancer. These studies support a role of SIRT1 in tumor suppression.
In contrast to the above mouse studies, numerous reports have shown upregulation of SIRT1 gene expression in both human and mouse cancers, and SIRT1 inhibition suppresses tumor growth as summarized in a recent review [17] . Using a bone marrow transduction/transplantation model of CML, Yuan et al. [8 && ] demonstrated that SIRT1 gene knockout significantly inhibits development of CML, providing the first genetic evidence that SIRT1 dysregulation by the oncogenic event is not merely a consequence of tumorigenesis, but is crucial for leukemia progression. Because BCR-ABL transduction of SIRT1 À/À bone marrow cells was conducted ex vivo, the effect of SIRT1 loss on inhibiting CML development is considered cell-autonomous. Also, it should be noted that contrary to in-vitro hematopoiesis described above, no significant difference was found between wildtype and knockout cells transduced with the control vector in the transplantation study in spite of steps for transducing cells in tissue culture [8 && ]. By examining SIRT1 overexpression in transgenic mice (SIRT1 tg ) with PTEN þ/À background, Herranz et al. [24] recently found that SIRT1 overexpression increases incidence of thyroid carcinomas and their lung metastasis, suggesting that increased SIRT1 gene expression plays a role in promoting tumor progression. In addition, Herranz et al. [24] showed that PTEN þ/À SIRT1 tg mice also develop prostate carcinomas in situ whereas PTEN þ/À or SIRT1 tg cohort mice do not [24] , indicating that SIRT1 overexpression may also have a role in promoting tumor initiation. Together, these studies provide strong genetic evidence that SIRT1 activation can facilitate not only BCR-ABLmediated leukemogenesis but also development of solid tumors.
SIRT1 PROMOTES LEUKEMIA STEM CELL SURVIVAL AND RESISTANCE TO BCR-ABL INHIBITORS
Several leukemias including CML are initiated and propagated by small populations of leukemia stem cells (LSC). LSC can resist elimination by standard therapies that target more mature cells, and persist after treatment as potential sources of relapse [25] . Although the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib mesylate is effective in inducing clinical remissions and prolonging survival in CML patients, primitive LSC are retained in patients achieving remission with TKI treatment [26, 27] . This is related to the resistance of primitive, quiescent CML LSC to apoptosis following TKI treatment despite effective inhibition of BCR-ABL kinase activity. Disease recurrence is usually seen following cessation of drug treatment, even in patients with undetectable BCR-ABL expression by q-PCR. CML patients currently need to take TKI treatment indefinitely, with risks of toxicity, lack of compliance, drug resistance, relapse, and associated expense.
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p53 Ku70 CML evolution and drug resistance FIGURE 1. A model for roles of SIRT1 in molecular pathobiology of chronic myeloid leukemia. SIRT1 is activated by BCR-ABL transformation in hematopoietic stem cells, in both kinase-dependent (through STAT5) and independent (indicated by ?) manners. SIRT1 activation suppresses functions of tumor suppressor p53 and promotes survival of chronic myeloid leukemia (CML) stem cells. Meanwhile, SIRT1 activates Ku70 functions to promote errorprone DNA damage repair, leading to acquisition of BCR-ABL mutations for CML evolution and drug resistance.
Li et al. [9 && ] have shown that SIRT1, a stress-related NAD þ -dependent deacetylase, is overexpressed in CML compared with normal CD34 þ CD38 À stem cells. SIRT1 inhibition, using RNAi or the pharmacological inhibitor tenovin-6 [28] , selectively decreased survival and proliferation of chronic phase and blast crisis CML LSC and sensitized them to TKI treatment. In-vivo treatment with tenovin-6 reduced CML LSC numbers, reduced LSC engraftment in secondary recipients, and prolonged survival after completion of treatment. These observations support an important role for SIRT1 in maintenance of CML LSC and their resistance to TKI treatment, and suggest that SIRT1 inhibition may represent a potential strategy to enhance elimination of LSC in CML patients treated with TKI.
The p53 gene is activated in response to genotoxic and oncogenic stress to induce cell-cycle arrest or apoptosis. Loss of p53 function is a common feature of human malignancies and contributes to early stages of cancer development [29] . Recent studies indicate that p53 inactivation is also required to maintain proliferation and survival of established malignancies, in the setting of continued oncogenic stress [9 && ]. SIRT1 knockdown using RNAi or the small molecule inhibitor tenovin-6 increased p53 acetylation and nuclear localization, and enhanced p53 target gene expression in CML progenitors. Knockdown of p53 or expression of an acetylation-defective p53 prevented SIRT1-mediated inhibition of CML progenitors [9 && ]. These results suggest that deacetylation of p53 by SIRT1 inhibits p53 activity and contributes to increased proliferation and preservation of CML LSC. These studies raise the possibility that other strategies to activate p53 could potentially be of benefit in targeting CML LSC. As SIRT1 affects multiple targets, other potential mechanisms such as activation of Foxo transcription factors or alteration in DNA repair mechanisms must also be considered.
SIRT1 PROMOTES ACQUIRED RESISTANCE OF CHRONIC MYELOID LEUKEMIA THROUGH MUTATIONS
Another important progress last year was the discovery that SIRT1 promotes acquisition of BCR-ABL mutations in CML cells for resistance to TKIs [30 && ]. Although imatinib remarkably increases 5-year survival of chronic phase CML patients [31] , the drug has only limited effect on patients in accelerated and blast crisis phases of the disease, who frequently relapse with acquisition of BCR-ABL kinase domain mutations [32, 33] . These mutations alter BCR-ABL conformation and prevent imatinib from access to its ATP-binding pocket [34] . Acquisition of genetic mutations is a major mechanism underlying cancer-acquired resistance with different molecular targets in a variety of cancers including CML, lung cancer, colon cancer, ovarian and breast cancer, and gastrointestinal cancer [35] . However, precise molecular mechanisms of how resistant mutations are actually acquired during cancer therapy are largely unknown.
Recently, Yuan et al. [36] have developed a novel culture model of CML acquired resistance based on a blast crisis CML cell line KCL-22. In this model, following initial apoptotic response, the cells rapidly acquire T315I BCR-ABL kinase domain mutation upon treatment with therapeutic concentrations of imatinib, recapitulating features of clinical BCR-ABL mutation acquisition. Yuan et al.
showed that most, if not all, BCR-ABL mutations are acquired de novo in this model. Using this model, Wang et al. [30 && ] showed that SIRT1 inhibition by gene knockdown or small molecules blocks acquisition of BCR-ABL mutations in CML cells and prevents CML cell relapse from TKIs. SIRT1 inhibition also effectively suppresses de-novo mutation acquisition of hypoxanthine phosphoribosyl transferase gene in CML and prostate cancer cells upon treatment of chemotherapeutic agent camptothecin. Wang et al. [30 && ] showed that suppression of mutation acquisition by SIRT1 inhibition does not require increased cell killing, and that SIRT1 promotes mutation acquisition in association with its ability to enhance error-prone DNA damage repair, particularly nonhomologous end joining (NHEJ), through deacetylating Ku70.
The findings by Wang et al. are surprising given that SIRT1 maintains genome stability [16, 22] and SIRT1 inhibition is expected to increase genetic instability and mutagenesis. However, it is important to note that although genetic instability is shown previously in SIRT1 À/À embryonic stem cells [16, 22] , impaired DNA damage response is similarly observed in SIRT1 À/À mouse embryonic fibroblasts [16] and in SIRT1 knockdown CML cells [30 && ]. SIRT1 knockdown reduces the efficiency of NHEJ and homologous recombination repair in both CML [30 && ] and osteosarcoma cells [22] . Therefore, a consensus role of SIRT1 has emerged for genome maintenance in both normal and cancer cells. But there may be an important distinction of the consequence of SIRT1-regulated DNA repair in normal versus cancer cells. In normal cells, DNA repair is typically a high-fidelity process, and SIRT1 promotes repair and reduces genetic lesions, leading to genome stability. Contradictorily, in cancer cells, DNA repair fidelity is compromised [37, 38] , and increased repair by SIRT1 may help cancer cell survival by avoiding catastrophic genomic events such as deletion of key oncogenes, but simultaneously allow accumulation of nonfatal genetic lesions and point mutations. By doing so, increased DNA repair mediated by SIRT1 may provide an incubation bed for accelerating cancer evolution and allow rapid acquisition of genetic mutations for drug resistance when cancer cells are under therapeutic stress [17, 39] . In this regard, it is important to note a recent study by Chakraborty et al. [40 & ] showing that CML stem and progenitor cells harbor chromosomal instability mediated by increased NHEJ repair. As SIRT1 expression increases further from chronic CML to advanced phases of the disease [8 && ], SIRT1-regulated error prone DNA repair may underlie CML evolution to higher malignant state. More studies are needed to further elucidate precise molecular mechanisms of SIRT1 in acquisition of BCR-ABL mutations for CML drug resistance and evolution. Such studies may shed novel insight on canceracquired resistance in general.
CONCLUSION
Several studies in the past year have revealed crucial roles of SIRT1 dysregulation in tumorigenesis, in particular, CML in which SIRT1 is activated by BCR-ABL. SIRT1 activation promotes BCR-ABLmediated leukemogenesis and CML stem cell resistance to imatinib, and facilitates acquisition of BCR-ABL mutations for CML acquired resistance. SIRT1 is a promising novel target for eradicating CML leukemic stem cells and residual disease with tyrosine kinase inhibitor treatment. Inhibition of SIRT1 may also prevent acquisition of BCR-ABL mutations in advanced phases of CML to inhibit acquired resistance and extend remission.
